APEX1 and cancer: There are already clinical studies aiming to inhibit APE1 in pancreatic, prostate, bladder, ovary, and other types of cancer (NCT0337508), and STAT3 (NCT00955812) in leukemia (Chu et al. 2019; Hayakawa et al. 2013).